FRANKFURT (dpa-AFX) - Schott Pharma shares suffered from a downgrade by analysts on Tuesday, finishing at the bottom of the MDax. The pharmaceutical packaging supplier's share price fell by 6.2 percent to 23.74 euros in the morning, approaching the record low of 22.64 euros recorded a few days before Christmas. The slide in the share price means that Schott's annual balance sheet for 2025 is negative again.

On Tuesday, Bank of America attracted attention when it turned its previous positive vote into a negative one. Marianne Bulot downgraded the shares by two levels from "Buy" to "Underperform".

The expert expects a weak first half of the fiscal year that will counteract the company's previous growth profile. She also remains cautious about a possible improvement in the further course of the year. Schott probably has a lot of unused capacity in the area of highly profitable polymer syringes, which is having a negative impact on margins. In this area, business is also heavily dependent on the customer Moderna, which entails risks. With a target price of EUR 23, she is now slightly below the current share price./tih/mis